Request a copy

Full Text

• Poirier P, Giles TD, Bray GA, et al. Obesity and cardio-vascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006; 113: 898-918
• Zalesin KC, Franklin BA, Miller WM, et al. Impact of obesity on cardiovascular disease. Endocrinol Metab Clin North Am 2008; 37: 663-684
• Greenway FL, Caruso MK. Safety of obesity drugs. Expert Opin Drug Saf 2005; 4: 1083-1095
• Robinson JR, Niswender KD. What are the risks and the benefits of current and emerging weight-loss medications? Curr Diab Rep 2009; 9: 368-375
• Kaul S, Bolger AF, Herrington D, et al. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation 2010; 121: 1868-1877
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471
• Sharma B, Henderson DC. Sibutramine: current status as an anti-obesity drug and its future perspectives. Expert Opin Pharmacother 2008; 9: 2161-2173
• Tziomalos K, Krassas GE, Tzotzas T. The use of sibu-tramine in the management of obesity and related disorders: an update. Vasc Health Risk Manag 2009; 5: 441-452
• Nisoli E, Carruba MO. A benefit-risk assessment of sibutramine in the management of obesity. Drug Saf 2003; 26: 1027-1048
• de Simone G, D'Addeo G. Sibutramine: balancing weight loss benefit and possible cardiovascular risk. Nutr Metab Cardiovasc Dis 2008; 18: 337-341
• James WPT. The SCOUT study: risk-benefit profile of si-butramine in overweight high-risk cardiovascular patients. Eur Heart J 2005; 7 Suppl. L: L44-8
• Caterson I, Coutinho W, Finer N, et al., for The SCOUT Investigators. Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT lead-in period. Obesity 2010; 18: 987-994
• Finer N, Executive Steering Committee of the Sibutramine Cardiovascular Outcome Trial. Withdrawal of sibu-tramine: editorial is judgment in advance of the facts. BMJ 2010 Mar 10; 340: c1346
• Harrison-Woolrych M, Ashton J, Herbison P. Fatal and non-fatal cardiovascular events in a general population prescribed sibutramine: a prospective cohort study. Drug Safety 2010; 33 (7): 605-613
• Perrio MJ, Wilton LV, Shakir SA. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England. Obesity 2007; 15: 2712-2722
• Calle EE, Thun MJ, Petrelli JM, et al. Body mass index and mortality in a prospective cohort study of US adults. N Engl J Med 1999; 341: 1097-1105
• Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in US deaths from coronary disease, 1980-2000. N Engl J Med 2007; 356: 2388-2398
• Gregg EW, Cheng YJ, Cadwell BL, et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA 2005; 293: 1868-1874
• Rosengren A, Eriksson H, Hansson PO, et al. Obesity and trends in cardiovascular risk factors over 40 years in Swedish men aged 50. J Intern Med 2009; 266: 268-276
• Rosengren A. Declining cardiovascular mortality and in-creasing obesity: a paradox. CMAJ 2009; 181: 127-128
• O'Flaherty M, Ford E, Allender S, et al. Coronary heart disease trends in England and Wales from 1984 to 2004: concealed levelling of mortality rates among young adults. Heart 2007; 94: 178-181
• Goldfine AB. Assessing the cardiovascular safety of diabetes therapies. N Engl J Med 2008; 359: 1092-1095